MXPA05008171A - Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida. - Google Patents

Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida.

Info

Publication number
MXPA05008171A
MXPA05008171A MXPA05008171A MXPA05008171A MXPA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A
Authority
MX
Mexico
Prior art keywords
phenyl
methyl
1lambda
thiomorpholin
dioxo
Prior art date
Application number
MXPA05008171A
Other languages
English (en)
Inventor
Schwitter Urs
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05008171A publication Critical patent/MXPA05008171A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una nueva modificacion cristalina de la 2-(3, 5-bis- trifluormetil- fenil)-N- [6-(1, 1-dioxo-1?6 -tiomorfolin-4 -il)-4 -(4-fluor-2 -metil -fenil)- piridin-3 -il] -N-metil -isobutiramida, caracterizada por el siguiente modelo de difraccion por rayos X, obtenido con una radiacion Cuk? a 2? (2teta)= 4.5, 6.4, 7.5, 7.7, 8.0, 8.2, 10.0, 10.2, 10.9, 11.1, 12.9, 13.4, 14.0, 14.5, 15.1, 15.6, 16.2, 16.5, 17.3, 17.5, 18.0, 18.9, 19.3, 19.5, 19.9, 20.1, 20.6, 21.0, 21.4, 22.7, 23.1, y 23.6 y un espectro de infrarrojos con bandas agudas a 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm-1, y en donde el punto de fusion extrapolado (DSC) es de 137.2°C.
MXPA05008171A 2003-01-31 2004-01-23 Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida. MXPA05008171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002134 2003-01-31
PCT/EP2004/000547 WO2004067007A1 (en) 2003-01-31 2004-01-23 NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE

Publications (1)

Publication Number Publication Date
MXPA05008171A true MXPA05008171A (es) 2005-10-05

Family

ID=32798734

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008171A MXPA05008171A (es) 2003-01-31 2004-01-23 Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida.

Country Status (28)

Country Link
US (1) US7160881B2 (es)
EP (1) EP1592428B1 (es)
JP (1) JP5026702B2 (es)
KR (1) KR100700421B1 (es)
CN (1) CN100562320C (es)
AR (1) AR042980A1 (es)
AT (1) ATE366576T1 (es)
AU (1) AU2004208483B8 (es)
BR (1) BRPI0406702A (es)
CA (1) CA2514037C (es)
CL (1) CL2004000150A1 (es)
CO (1) CO5580750A2 (es)
DE (1) DE602004007486T2 (es)
ES (1) ES2290666T3 (es)
GT (1) GT200400009A (es)
HR (1) HRP20050664A2 (es)
IL (1) IL169600A (es)
MX (1) MXPA05008171A (es)
MY (1) MY135785A (es)
NO (1) NO20053431L (es)
NZ (1) NZ541243A (es)
PA (1) PA8594601A1 (es)
PE (1) PE20040944A1 (es)
PL (1) PL378404A1 (es)
RU (1) RU2330022C2 (es)
TW (1) TWI293294B (es)
WO (1) WO2004067007A1 (es)
ZA (1) ZA200505567B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
EP2470545B1 (en) * 2009-08-27 2013-10-09 NeRRe Therapeutics Limited Anhydrate forms of a pyridine derivative
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DK0737192T3 (da) 1993-12-29 2001-11-26 Merck Sharp & Dohme Substituerede morpholinderivater og deres anvendelse som terapeutiske midler
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DE60014216T2 (de) 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
ES2261657T3 (es) * 2001-04-23 2006-11-16 F. Hoffman-La Roche Ag Derivados de hidrazida del acido pirrolidin-2-carboxilico para uso como inhibidores de metaloproteasa.
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
ATE366576T1 (de) 2007-08-15
WO2004067007A1 (en) 2004-08-12
JP2006514999A (ja) 2006-05-18
EP1592428A1 (en) 2005-11-09
AR042980A1 (es) 2005-07-13
CL2004000150A1 (es) 2005-01-07
KR20050096964A (ko) 2005-10-06
US7160881B2 (en) 2007-01-09
PL378404A1 (pl) 2006-04-03
TW200510358A (en) 2005-03-16
ZA200505567B (en) 2007-05-30
GT200400009A (es) 2004-12-01
HRP20050664A2 (en) 2006-12-31
IL169600A (en) 2010-11-30
NZ541243A (en) 2008-04-30
RU2005127216A (ru) 2006-04-10
AU2004208483B8 (en) 2008-04-03
DE602004007486D1 (de) 2007-08-23
DE602004007486T2 (de) 2008-04-30
JP5026702B2 (ja) 2012-09-19
CN100562320C (zh) 2009-11-25
NO20053431D0 (no) 2005-07-14
NO20053431L (no) 2005-10-05
PE20040944A1 (es) 2004-12-14
RU2330022C2 (ru) 2008-07-27
ES2290666T3 (es) 2008-02-16
BRPI0406702A (pt) 2005-12-20
CN1744900A (zh) 2006-03-08
MY135785A (en) 2008-06-30
AU2004208483B2 (en) 2008-03-06
TWI293294B (en) 2008-02-11
CA2514037A1 (en) 2004-08-12
KR100700421B1 (ko) 2007-03-28
US20040186100A1 (en) 2004-09-23
AU2004208483A1 (en) 2004-08-12
CO5580750A2 (es) 2005-11-30
CA2514037C (en) 2012-03-13
PA8594601A1 (es) 2004-09-16
EP1592428B1 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
FR12C0074I2 (fr) Composes 1,2-dihydropyridine, leur procede de preparation et leur utilisation
WO2001056990A3 (en) Pyridine derivates as potentiators of glutamate receptors
PL372944A1 (en) 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
WO2003028728A8 (en) 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands
WO2004013131A3 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
AU1676200A (en) Polyhydroxylated heterocyclic derivatives as anti-coagulants
IL168416A (en) Process for the preparation of 2-aminomethylpyridine derivative
DE69613710T2 (de) Benzoxazepinverbindungen, ihre herstellung und verwendung als lipidsenker
MY110142A (en) Thiazolidinedione derivatives, their production and use
ME00061B (me) Nova kristalna modifikacija anhidrata boskalida
MXPA05008171A (es) Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida.
HU9700886D0 (en) New intermediates and process for producing them
WO2002060874A8 (en) Potassium channel inhibitors
TWI318625B (en) Process for the preparation of 2-aminomethylpyridine derivative
TW328951B (en) Substituted 2-phenylpyridines
MXPA03012073A (es) Amidoderivados heterociclicos.
EP1496059A4 (en) CONDENSED BICYCLIC PYRIMIDINE DERIVATIVES
EP0671396A4 (en) METHOD FOR PRODUCING 2-SUBSTITUTED BENZO (b) THIOPHENES.
EP1065202A4 (en) 6- (ALPHA-FLUOROALKYL) -4-PYRIMIDONES AND THEIR PRODUCTION PROCESS
NO964386L (no) Nye krystallformer av 1-[5-metansulfonamidoindolyl-2-karbonylÅ-4-[3-(1-metyletylamino)-2-pyridinylÅpiperazin
IN184757B (es)
WO2002086099A3 (de) Exopolysaccharidproduktion
AU2003248059A1 (en) NOVEL Alpha-KETOAMIDE DERIVATIVE AND USE THEREOF
Berthold et al. The Variable Period of RY Canis Minoris BAV Mitteilungen Nr. 127
WO2002012459A3 (de) Verfahren zur verbesserten herstellung von cyanophycin und dessen folgeprodukte

Legal Events

Date Code Title Description
FG Grant or registration